Marker Therapeutics (MRKR) Receivables - Net (2022 - 2025)
Marker Therapeutics (MRKR) has disclosed Receivables - Net for 4 consecutive years, with $200000.0 as the latest value for Q3 2025.
- Quarterly Receivables - Net rose 900.0% to $200000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Sep 2025, up 900.0% year-over-year, with the annual reading at $9.5 million for FY2024, 1800.0% up from the prior year.
- Receivables - Net for Q3 2025 was $200000.0 at Marker Therapeutics, down from $2.3 million in the prior quarter.
- The five-year high for Receivables - Net was $9.5 million in Q4 2024, with the low at $20000.0 in Q3 2024.
- Average Receivables - Net over 4 years is $2.0 million, with a median of $1.8 million recorded in 2023.
- Peak annual rise in Receivables - Net hit 1800.0% in 2024, while the deepest fall reached 90.0% in 2024.
- Over 4 years, Receivables - Net stood at $2.0 million in 2022, then tumbled by 75.0% to $500000.0 in 2023, then soared by 1800.0% to $9.5 million in 2024, then tumbled by 97.89% to $200000.0 in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $200000.0, $2.3 million, and $9.5 million for Q3 2025, Q1 2025, and Q4 2024 respectively.